Abstract
Neurodegenerative diseases are becoming an ever-increasing problem in aging populations. Low levels of brain-derived neurotrophic factor (BDNF) have previously been associated with the pathogenesis of numerous neurodegenerative diseases. Recently, microRNAs (miRNAs) have been proposed as potential novel therapeutic targets for treating various diseases of the central nervous system (CNS), and interestingly, few studies have reported several miRNAs that downregulate the expression levels of BDNF. However, substantial challenges exist when attempting to translate these findings into practical anti-miRNA therapeutics, especially when the targets remain inside the CNS. Thus, in this review, we summarize the specific molecular mechanisms by which several miRNAs negatively modulate the expressions of BDNF, address the potential clinical difficulties that can be faced during the development of anti-miRNA-based therapeutics and propose strategies to overcome these challenges.
Similar content being viewed by others
References
Aagaard, L., & Rossi, J. J. (2007). RNAi therapeutics: Principles, prospects and challenges. Advanced Drug Delivery Reviews, 59(2–3), 75–86. doi:10.1016/j.addr.2007.03.005.
Ahlskog, J. E. (2011). Does vigorous exercise have a neuroprotective effect in Parkinson disease? Neurology, 77(3), 288–294. doi:10.1212/WNL.0b013e318225ab66.
Angelucci, F., Piermaria, J., Gelfo, F., Shofany, J., Tramontano, M., Fiore, M., et al. (2016). The effects of motor rehabilitation training on clinical symptoms and serum BDNF levels in Parkinson’s disease subjects. Canadian Journal of Physiology and Pharmacology. doi:10.1139/cjpp-2015-0322.
Autry, A. E., & Monteggia, L. M. (2012). Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacological Reviews, 64(2), 238–258. doi:10.1124/pr.111.005108.
Barnham, K. J., Masters, C. L., & Bush, A. I. (2004). Neurodegenerative diseases and oxidative stress. Nature Reviews Drug Discovery, 3(3), 205–214. doi:10.1038/nrd1330.
Berchtold, N. C., Chinn, G., Chou, M., Kesslak, J. P., & Cotman, C. W. (2005). Exercise primes a molecular memory for brain-derived neurotrophic factor protein induction in the rat hippocampus. Neuroscience, 133(3), 853–861. doi:10.1016/j.neuroscience.2005.03.026.
Berchtold, N. C., Kesslak, J. P., Pike, C. J., Adlard, P. A., & Cotman, C. W. (2001). Estrogen and exercise interact to regulate brain-derived neurotrophic factor mRNA and protein expression in the hippocampus. European Journal of Neuroscience, 14(12), 1992–2002.
Bibel, M., & Barde, Y.-A. (2000). Neurotrophins: Key regulators of cell fate and cell shape in the vertebrate nervous system. Genes & Development, 14(23), 2919–2937.
Bredy, T. W., Lin, Q., Wei, W., Baker-Andresen, D., & Mattick, J. S. (2011). MicroRNA regulation of neural plasticity and memory. Neurobiology of Learning and Memory, 96(1), 89–94. doi:10.1016/j.nlm.2011.04.004.
Buchman, A. S., Yu, L., Boyle, P. A., Schneider, J. A., De Jager, P. L., & Bennett, D. A. (2016). Higher brain BDNF gene expression is associated with slower cognitive decline in older adults. Neurology, 86(8), 735–741. doi:10.1212/wnl.0000000000002387.
Bumcrot, D., Manoharan, M., Koteliansky, V., & Sah, D. W. (2006). RNAi therapeutics: A potential new class of pharmaceutical drugs. Nature Chemical Biology, 2(12), 711–719. doi:10.1038/nchembio839.
Cao, L., Lin, E. J., Cahill, M. C., Wang, C., Liu, X., & During, M. J. (2009). Molecular therapy of obesity and diabetes by a physiological autoregulatory approach. Nature Medicine, 15(4), 447–454. doi:10.1038/nm.1933.
Caputo, V., Sinibaldi, L., Fiorentino, A., Parisi, C., Catalanotto, C., Pasini, A., et al. (2011). Brain derived neurotrophic factor (BDNF) expression is regulated by microRNAs miR-26a and miR-26b allele-specific binding. PLoS One, 6(12), e28656.
Carthew, R. W., & Sontheimer, E. J. (2009). Origins and mechanisms of miRNAs and siRNAs. Cell, 136(4), 642–655.
Chen, Y., Zhu, X., Zhang, X., Liu, B., & Huang, L. (2010). Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Molecular Therapy, 18(9), 1650–1656. doi:10.1038/mt.2010.136.
Cogswell, J. P., Ward, J., Taylor, I. A., Waters, M., Shi, Y., Cannon, B., et al. (2008). Identification of miRNA changes in Alzheimer’s disease brain and CSF yields putative biomarkers and insights into disease pathways. Journal of Alzheimer’s Disease, 14(1), 27–41.
Colbert, L. H., Visser, M., Simonsick, E. M., Tracy, R. P., Newman, A. B., Kritchevsky, S. B., et al. (2004). Physical activity, exercise, and inflammatory markers in older adults: Findings from the Health, Aging and Body Composition Study. Journal of the American Geriatrics Society, 52(7), 1098–1104. doi:10.1111/j.1532-5415.2004.52307.x.
Cruickshank, T. M., Thompson, J. A., Dominguez, D. J., Reyes, A. P., Bynevelt, M., Georgiou-Karistianis, N., et al. (2015). The effect of multidisciplinary rehabilitation on brain structure and cognition in Huntington’s disease: An exploratory study. Brain and Behavior, 5(2), e00312. doi:10.1002/brb3.312.
Davis, S., Propp, S., Freier, S. M., Jones, L. E., Serra, M. J., Kinberger, G., et al. (2009). Potent inhibition of microRNA in vivo without degradation. Nucleic Acids Research, 37(1), 70–77.
de Fougerolles, A., Vornlocher, H. P., Maraganore, J., & Lieberman, J. (2007). Interfering with disease: A progress report on siRNA-based therapeutics. Nature Reviews Drug Discovery, 6(6), 443–453. doi:10.1038/nrd2310.
Ding, Q., Vaynman, S., Akhavan, M., Ying, Z., & Gomez-Pinilla, F. (2006). Insulin-like growth factor I interfaces with brain-derived neurotrophic factor-mediated synaptic plasticity to modulate aspects of exercise-induced cognitive function. Neuroscience, 140(3), 823–833. doi:10.1016/j.neuroscience.2006.02.084.
Diniz, B. S., & Teixeira, A. L. (2011). Brain-derived neurotrophic factor and Alzheimer’s disease: Physiopathology and beyond. Neuromolecular Medicine, 13(4), 217–222. doi:10.1007/s12017-011-8154-x.
Ellis, T., Cavanaugh, J. T., Earhart, G. M., Ford, M. P., Foreman, K. B., Fredman, L., et al. (2011). Factors associated with exercise behavior in people with Parkinson disease. Physical Therapy, 91(12), 1838–1848. doi:10.2522/ptj.20100390.
Erickson, K. I., Miller, D. L., & Roecklein, K. A. (2012). The aging hippocampus: Interactions between exercise, depression, and BDNF. Neuroscientist, 18(1), 82–97. doi:10.1177/1073858410397054.
Erickson, K. I., Voss, M. W., Prakash, R. S., Basak, C., Szabo, A., Chaddock, L., et al. (2011). Exercise training increases size of hippocampus and improves memory. Proceedings of the National Academy of Sciences USA, 108(7), 3017–3022. doi:10.1073/pnas.1015950108.
Ferrer, I., Goutan, E., Marin, C., Rey, M. J., & Ribalta, T. (2000). Brain-derived neurotrophic factor in Huntington disease. Brain Research, 866(1–2), 257–261.
Forero, D. A., van der Ven, K., Callaerts, P., & Del-Favero, J. (2010). miRNA genes and the brain: Implications for psychiatric disorders. Human Mutation, 31(11), 1195–1204. doi:10.1002/humu.21344.
Fukuda, T., Itoh, M., Ichikawa, T., Washiyama, K., & Goto, Y. (2005). Delayed maturation of neuronal architecture and synaptogenesis in cerebral cortex of Mecp2-deficient mice. Journal of Neuropathology and Experimental Neurology, 64(6), 537–544.
Gao, J., Wang, W.-Y., Mao, Y.-W., Gräff, J., Guan, J.-S., Pan, L., et al. (2010). A novel pathway regulates memory and plasticity via SIRT1 and miR-134. Nature, 466(7310), 1105–1109.
Garcia-Mesa, Y., Pareja-Galeano, H., Bonet-Costa, V., Revilla, S., Gomez-Cabrera, M. C., Gambini, J., et al. (2014). Physical exercise neuroprotects ovariectomized 3xTg-AD mice through BDNF mechanisms. Psychoneuroendocrinology, 45, 154–166. doi:10.1016/j.psyneuen.2014.03.021.
Garzon, R., Marcucci, G., & Croce, C. M. (2010). Targeting microRNAs in cancer: Rationale, strategies and challenges. Nature Reviews Drug Discovery, 9(10), 775–789. doi:10.1038/nrd3179.
Georges, M., Coppieters, W., & Charlier, C. (2007). Polymorphic miRNA-mediated gene regulation: Contribution to phenotypic variation and disease. Current Opinion in Genetics & Development, 17(3), 166–176.
Ghose, J., Sinha, M., Das, E., Jana, N. R., & Bhattacharyya, N. P. (2011). Regulation of miR-146a by RelA/NFkB and p53 in STHdh(Q111)/Hdh(Q111) cells, a cell model of Huntington’s disease. PLoS One, 6(8), e23837. doi:10.1371/journal.pone.0023837.
Gomez-Pinilla, F., Ying, Z., Roy, R. R., Molteni, R., & Edgerton, V. R. (2002). Voluntary exercise induces a BDNF-mediated mechanism that promotes neuroplasticity. Journal of Neurophysiology, 88(5), 2187–2195. doi:10.1152/jn.00152.2002.
Guidi, M., Muinos-Gimeno, M., Kagerbauer, B., Marti, E., Estivill, X., & Espinosa-Parrilla, Y. (2010). Overexpression of miR-128 specifically inhibits the truncated isoform of NTRK3 and upregulates BCL2 in SH-SY5Y neuroblastoma cells. BMC Molecular Biology, 11, 95. doi:10.1186/1471-2199-11-95.
Ha, M., & Kim, V. N. (2014). Regulation of microRNA biogenesis. Nature Reviews Molecular Cell Biology, 15(8), 509–524.
Hass, C. J., Buckley, T. A., Pitsikoulis, C., & Barthelemy, E. J. (2012). Progressive resistance training improves gait initiation in individuals with Parkinson’s disease. Gait Posture, 35(4), 669–673. doi:10.1016/j.gaitpost.2011.12.022.
Hendrickson, D. G., Hogan, D. J., McCullough, H. L., Myers, J. W., Herschlag, D., Ferrell, J. E., et al. (2009). Concordant regulation of translation and mRNA abundance for hundreds of targets of a human microRNA. PLoS Biology, 7(11), e1000238.
Herman, T., Giladi, N., & Hausdorff, J. M. (2009). Treadmill training for the treatment of gait disturbances in people with Parkinson’s disease: A mini-review. J Neural Transm (Vienna), 116(3), 307–318. doi:10.1007/s00702-008-0139-z.
Hernandez, S. S., Sandreschi, P. F., da Silva, F. C., Arancibia, B. A., da Silva, R., Gutierres, P. J., et al. (2015). What are the benefits of exercise for Alzheimer’s disease? A systematic review of the past 10 years. Journal of Aging, Physical Activity, 23(4), 659–668. doi:10.1123/japa.2014-0180.
Hutvágner, G., Simard, M. J., Mello, C. C., & Zamore, P. D. (2004). Sequence-specific inhibition of small RNA function. PLoS Biology, 2(4), e98.
Im, H.-I., Hollander, J. A., Bali, P., & Kenny, P. J. (2010). MeCP2 controls BDNF expression and cocaine intake through homeostatic interactions with microRNA-212. Nature Neuroscience, 13(9), 1120–1127.
Inukai, S., de Lencastre, A., Turner, M., & Slack, F. (2012). Novel microRNAs differentially expressed during aging in the mouse brain. PLoS One, 7(7), e40028. doi:10.1371/journal.pone.0040028.
Irmady, K., Jackman, K. A., Padow, V. A., Shahani, N., Martin, L. A., Cerchietti, L., et al. (2014). Mir-592 regulates the induction and cell death-promoting activity of p75NTR in neuronal ischemic injury. Journal of Neuroscience, 34(9), 3419–3428. doi:10.1523/jneurosci.1982-13.2014.
Jimenez-Mateos, E. M., Engel, T., Merino-Serrais, P., McKiernan, R. C., Tanaka, K., Mouri, G., et al. (2012). Silencing microRNA-134 produces neuroprotective and prolonged seizure-suppressive effects. Nature Medicine, 18(7), 1087–1094. doi:10.1038/nm.2834.
Johannessen, M., Delghandi, M. P., & Moens, U. (2004). What turns CREB on? Cellular Signalling, 16(11), 1211–1227. doi:10.1016/j.cellsig.2004.05.001.
Jugloff, D. G., Jung, B. P., Purushotham, D., Logan, R., & Eubanks, J. H. (2005). Increased dendritic complexity and axonal length in cultured mouse cortical neurons overexpressing methyl-CpG-binding protein MeCP2. Neurobiology of Diseases, 19(1–2), 18–27. doi:10.1016/j.nbd.2004.11.002.
Karege, F., Schwald, M., & Cisse, M. (2002). Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neuroscience Letters, 328(3), 261–264.
Keifer, J., Zheng, Z., & Ambigapathy, G. (2015). A MicroRNA-BDNF negative feedback signaling loop in brain: Implications for Alzheimer’s disease. MicroRNA, 4(2), 101–108.
Klein, M. E., Lioy, D. T., Ma, L., Impey, S., Mandel, G., & Goodman, R. H. (2007). Homeostatic regulation of MeCP2 expression by a CREB-induced microRNA. Nature Neuroscience, 10(12), 1513–1514.
Kocerha, J., Kauppinen, S., & Wahlestedt, C. (2009). microRNAs in CNS disorders. Neuromolecular Medicine, 11(3), 162–172.
Kolbeck, R., Bartke, I., Eberle, W., & Barde, Y. A. (1999). Brain-derived neurotrophic factor levels in the nervous system of wild-type and neurotrophin gene mutant mice. Journal of Neurochemistry, 72(5), 1930–1938.
Konopka, W., Kiryk, A., Novak, M., Herwerth, M., Parkitna, J. R., Wawrzyniak, M., et al. (2010). MicroRNA loss enhances learning and memory in mice. The Journal of Neuroscience, 30(44), 14835–14842.
Kosik, K. S., & Krichevsky, A. M. (2005). The elegance of the MicroRNAs: A neuronal perspective. Neuron, 47(6), 779–782. doi:10.1016/j.neuron.2005.08.019.
Krol, J., Busskamp, V., Markiewicz, I., Stadler, M. B., Ribi, S., Richter, J., et al. (2010). Characterizing light-regulated retinal microRNAs reveals rapid turnover as a common property of neuronal microRNAs. Cell, 141(4), 618–631. doi:10.1016/j.cell.2010.03.039.
Krutzfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., et al. (2005). Silencing of microRNAs in vivo with ‘antagomirs’. Nature, 438(7068), 685–689. doi:10.1038/nature04303.
Lee, S. T., Chu, K., Jung, K. H., Kim, J. H., Huh, J. Y., Yoon, H., et al. (2012). miR-206 regulates brain-derived neurotrophic factor in Alzheimer disease model. Annals of Neurology, 72(2), 269–277.
Lee, J., Fukumoto, H., Orne, J., Klucken, J., Raju, S., Vanderburg, C. R., et al. (2005). Decreased levels of BDNF protein in Alzheimer temporal cortex are independent of BDNF polymorphisms. Experimental Neurology, 194(1), 91–96. doi:10.1016/j.expneurol.2005.01.026.
Lee, R., Kermani, P., Teng, K. K., & Hempstead, B. L. (2001). Regulation of cell survival by secreted proneurotrophins. Science, 294(5548), 1945–1948. doi:10.1126/science.1065057.
Liang, H., & Li, W.-H. (2007). MicroRNA regulation of human protein–protein interaction network. RNA, 13(9), 1402–1408.
Lima, L. O., Scianni, A., & Rodrigues-de-Paula, F. (2013). Progressive resistance exercise improves strength and physical performance in people with mild to moderate Parkinson’s disease: A systematic review. Journal of Physiotherapy, 59(1), 7–13. doi:10.1016/S1836-9553(13)70141-3.
Lindvall, O., Kokaia, Z., Bengzon, J., Elmer, E., & Kokaia, M. (1994). Neurotrophins and brain insults. Trends in Neurosciences, 17(11), 490–496.
Liu, D.-Y., Shen, X.-M., Yuan, F.-F., Guo, O.-Y., Zhong, Y., Chen, J.-G., et al. (2014). The physiology of BDNF and its relationship with ADHD. Molecular Neurobiology, 52(3), 1467–1476.
Lu, B., Nagappan, G., Guan, X., Nathan, P. J., & Wren, P. (2013). BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases. Nature Reviews Neuroscience, 14(6), 401–416.
Lu, B., Pang, P. T., & Woo, N. H. (2005). The yin and yang of neurotrophin action. Nature Reviews Neuroscience, 6(8), 603–614.
Lukiw, W. J. (2012). NF-small ka, CyrillicB-regulated micro RNAs (miRNAs) in primary human brain cells. Experimental Neurology, 235(2), 484–490. doi:10.1016/j.expneurol.2011.11.022.
Maes, O. C., Chertkow, H. M., Wang, E., & Schipper, H. M. (2009). MicroRNA: Implications for Alzheimer disease and other human CNS disorders. Current Genomics, 10(3), 154.
Maisonpierre, P. C., Belluscio, L., Friedman, B., Alderson, R. F., Wiegand, S. J., Furth, M. E., et al. (1990). NT-3, BDNF, and NGF in the developing rat nervous system: Parallel as well as reciprocal patterns of expression. Neuron, 5(4), 501–509.
Marti, E., Pantano, L., Banez-Coronel, M., Llorens, F., Minones-Moyano, E., Porta, S., et al. (2010). A myriad of miRNA variants in control and Huntington’s disease brain regions detected by massively parallel sequencing. Nucleic Acids Research, 38(20), 7219–7235. doi:10.1093/nar/gkq575.
Mellios, N., Huang, H.-S., Grigorenko, A., Rogaev, E., & Akbarian, S. (2008). A set of differentially expressed miRNAs, including miR-30a-5p, act as post-transcriptional inhibitors of BDNF in prefrontal cortex. Human Molecular Genetics, 17(19), 3030–3042.
Menzies, F. M., Fleming, A., & Rubinsztein, D. C. (2015). Compromised autophagy and neurodegenerative diseases. Nature Reviews Neuroscience, 16(6), 345–357. doi:10.1038/nrn3961.
Miura, P., Amirouche, A., Clow, C., Belanger, G., & Jasmin, B. J. (2012). Brain-derived neurotrophic factor expression is repressed during myogenic differentiation by miR-206. Journal of Neurochemistry, 120(2), 230–238. doi:10.1111/j.1471-4159.2011.07583.x.
Murer, M. G., Yan, Q., & Raisman-Vozari, R. (2001). Brain-derived neurotrophic factor in the control human brain, and in Alzheimer’s disease and Parkinson’s disease. Progress in Neurobiology, 63(1), 71–124.
Nagahara, A. H., & Tuszynski, M. H. (2011). Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nature Reviews Drug Discovery, 10(3), 209–219.
Narisawa-Saito, M., Wakabayashi, K., Tsuji, S., Takahashi, H., & Nawa, H. (1996). Regional specificity of alterations in NGF, BDNF and NT-3 levels in Alzheimer’s disease. Neuroreport, 7(18), 2925–2928.
Ninan, I. (2014). Synaptic regulation of affective behaviors; role of BDNF. Neuropharmacology, 76 Pt C, 684–695. doi:10.1016/j.neuropharm.2013.04.011.
Pang, P. T., Teng, H. K., Zaitsev, E., Woo, N. T., Sakata, K., Zhen, S., et al. (2004). Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity. Science, 306(5695), 487–491. doi:10.1126/science.1100135.
Pareja-Galeano, H., Garatachea, N., & Lucia, A. (2015). Exercise as a polypill for chronic diseases. Progress in Molecular Biology and Translational Science, 135, 497–526. doi:10.1016/bs.pmbts.2015.07.019.
Peedicayil, J. (2015). Epigenetic targets for the treatment of neurodegenerative diseases. Clinical Pharmacology and Therapeutics,. doi:10.1002/cpt.323.
Peng, S., Wuu, J., Mufson, E. J., & Fahnestock, M. (2005). Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer’s disease. Journal of Neurochemistry, 93(6), 1412–1421. doi:10.1111/j.1471-4159.2005.03135.x.
Petersen, M., Bondensgaard, K., Wengel, J., & Jacobsen, J. P. (2002). Locked nucleic acid (LNA) recognition of RNA: NMR solution structures of LNA: RNA hybrids. Journal of the American Chemical Society, 124(21), 5974–5982.
Petersen, M., & Wengel, J. (2003). LNA: A versatile tool for therapeutics and genomics. Trends in Biotechnology, 21(2), 74–81.
Phillips, H. S., Hains, J. M., Armanini, M., Laramee, G. R., Johnson, S. A., & Winslow, J. W. (1991). BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer’s disease. Neuron, 7(5), 695–702.
Remenyi, J., Hunter, C., Cole, C., Ando, H., Impey, S., Monk, C., et al. (2010). Regulation of the miR-212/132 locus by MSK1 and CREB in response to neurotrophins. Biochemical Journal, 428, 281–291.
Salta, E., & De Strooper, B. (2012). Non-coding RNAs with essential roles in neurodegenerative disorders. Lancet Neurology, 11(2), 189–200. doi:10.1016/S1474-4422(11)70286-1.
Schratt, G. M., Tuebing, F., Nigh, E. A., Kane, C. G., Sabatini, M. E., Kiebler, M., et al. (2006). A brain-specific microRNA regulates dendritic spine development. Nature, 439(7074), 283–289.
Sethi, P., & Lukiw, W. J. (2009). Micro-RNA abundance and stability in human brain: Specific alterations in Alzheimer’s disease temporal lobe neocortex. Neuroscience Letters, 459(2), 100–104.
Sethupathy, P., Borel, C., Gagnebin, M., Grant, G. R., Deutsch, S., Elton, T. S., et al. (2007). Human microRNA-155 on chromosome 21 differentially interacts with its polymorphic target in the AGTR1 3′ untranslated region: A mechanism for functional single-nucleotide polymorphisms related to phenotypes. The American Journal of Human Genetics, 81(2), 405–413.
Sheinerman, K. S., Tsivinsky, V. G., Crawford, F., Mullan, M. J., Abdullah, L., & Umansky, S. R. (2012). Plasma microRNA biomarkers for detection of mild cognitive impairment. Aging (Albany NY), 4(9), 590.
Shumaker, S. A., Legault, C., Rapp, S. R., Thal, L., Wallace, R. B., Ockene, J. K., et al. (2003). Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The Women’s Health Initiative Memory Study—a randomized controlled trial. JAMA, 289(20), 2651–2662. doi:10.1001/jama.289.20.2651.
Silva, A. J., Kogan, J. H., Frankland, P. W., & Kida, S. (1998). CREB and memory. The Annual Review of Neuroscience, 21, 127–148. doi:10.1146/annurev.neuro.21.1.127.
Solum, D. T., & Handa, R. J. (2002). Estrogen regulates the development of brain-derived neurotrophic factor mRNA and protein in the rat hippocampus. Journal of Neuroscience, 22(7), 2650–2659.
Soto, C. (2003). Unfolding the role of protein misfolding in neurodegenerative diseases. Nature Reviews Neuroscience, 4(1), 49–60. doi:10.1038/nrn1007.
Tapia-Arancibia, L., Rage, F., Givalois, L., & Arancibia, S. (2004). Physiology of BDNF: Focus on hypothalamic function. Frontiers in Neuroendocrinology, 25(2), 77–107.
Teng, H. K., Teng, K. K., Lee, R., Wright, S., Tevar, S., Almeida, R. D., et al. (2005). ProBDNF induces neuronal apoptosis via activation of a receptor complex of p75NTR and sortilin. Journal of Neuroscience, 25(22), 5455–5463. doi:10.1523/JNEUROSCI.5123-04.2005.
Underwood, C. K., & Coulson, E. J. (2008). The p75 neurotrophin receptor. International Journal of Biochemistry & Cell Biology, 40(9), 1664–1668. doi:10.1016/j.biocel.2007.06.010.
Vorhies, J. S., & Nemunaitis, J. (2007). Nonviral delivery vehicles for use in short hairpin RNA-based cancer therapies. Expert Review of Anticancer Therapy, 7(3), 373–382. doi:10.1586/14737140.7.3.373.
Wayman, G. A., Davare, M., Ando, H., Fortin, D., Varlamova, O., Cheng, H. Y., et al. (2008). An activity-regulated microRNA controls dendritic plasticity by down-regulating p250GAP. Proceedings of the National Academy of Sciences of the USA, 105(26), 9093–9098. doi:10.1073/pnas.0803072105.
Widenfalk, J., Olson, L., & Thoren, P. (1999). Deprived of habitual running, rats downregulate BDNF and TrkB messages in the brain. Neuroscience Research, 34(3), 125–132.
Wu, Y. W., Du, X., van den Buuse, M., & Hill, R. A. (2015). Analyzing the influence of BDNF heterozygosity on spatial memory response to 17beta-estradiol. Translational Psychiatry, 5, e498. doi:10.1038/tp.2014.143.
Wu, J., & Xie, X. (2006). Comparative sequence analysis reveals an intricate network among REST, CREB and miRNA in mediating neuronal gene expression. Genome Biology, 7(9), R85. doi:10.1186/gb-2006-7-9-r85.
Xu, B., Goulding, E. H., Zang, K., Cepoi, D., Cone, R. D., Jones, K. R., et al. (2003). Brain-derived neurotrophic factor regulates energy balance downstream of melanocortin-4 receptor. Nature Neuroscience, 6(7), 736–742. doi:10.1038/nn1073.
Yaffe, K., Krueger, K., Cummings, S. R., Blackwell, T., Henderson, V. W., Sarkar, S., et al. (2005). Effect of raloxifene on prevention of dementia and cognitive impairment in older women: The Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. American Journal of Psychiatry, 162(4), 683–690. doi:10.1176/appi.ajp.162.4.683.
Yamashita, T., Tucker, K. L., & Barde, Y. A. (1999). Neurotrophin binding to the p75 receptor modulates Rho activity and axonal outgrowth. Neuron, 24(3), 585–593.
Yang, G., Song, Y., Zhou, X., Deng, Y., Liu, T., Weng, G., et al. (2015). DNA methyltransferase 3, a target of microRNA-29c, contributes to neuronal proliferation by regulating the expression of brain-derived neurotrophic factor. Molecular Medicine Reports, 12(1), 1435–1442. doi:10.3892/mmr.2015.3531.
Yarrow, J. F., White, L. J., McCoy, S. C., & Borst, S. E. (2010). Training augments resistance exercise induced elevation of circulating brain derived neurotrophic factor (BDNF). Neuroscience Letters, 479(2), 161–165. doi:10.1016/j.neulet.2010.05.058.
Yuan, X. B., Jin, M., Xu, X., Song, Y. Q., Wu, C. P., Poo, M. M., et al. (2003). Signalling and crosstalk of Rho GTPases in mediating axon guidance. Nature Cell Biology, 5(1), 38–45. doi:10.1038/ncb895.
Zhao, Y.-N., Li, W.-F., Li, F., Zhang, Z., Dai, Y.-D., Xu, A.-L., et al. (2013). Resveratrol improves learning and memory in normally aged mice through microRNA-CREB pathway. Biochemical and Biophysical Research Communications, 435(4), 597–602. doi:10.1016/j.bbrc.2013.05.025.
Zhao, X., Pan, F., Holt, C. M., Lewis, A. L., & Lu, J. R. (2009). Controlled delivery of antisense oligonucleotides: A brief review of current strategies. Expert Opinion on Drug Delivery, 6(7), 673–686. doi:10.1517/17425240902992894.
Zuccato, C., & Cattaneo, E. (2007). Role of brain-derived neurotrophic factor in Huntington’s disease. Progress in Neurobiology, 81(5–6), 294–330. doi:10.1016/j.pneurobio.2007.01.003.
Zuccato, C., Ciammola, A., Rigamonti, D., Leavitt, B. R., Goffredo, D., Conti, L., et al. (2001). Loss of huntingtin-mediated BDNF gene transcription in Huntington’s disease. Science, 293(5529), 493–498. doi:10.1126/science.1059581.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Hwa Jeong You and Jae Hyon Park have contributed equally to this work.
Rights and permissions
About this article
Cite this article
You, H.J., Park, J.H., Pareja-Galeano, H. et al. Targeting MicroRNAs Involved in the BDNF Signaling Impairment in Neurodegenerative Diseases. Neuromol Med 18, 540–550 (2016). https://doi.org/10.1007/s12017-016-8407-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12017-016-8407-9